Sponsors

Gold Sponsors

With nearly 700 lawyers in 12 offices, we represent clients that consist primarily of substantial businesses, healthcare providers, money and asset managers and investors, ranging from mid-sized enterprises to Fortune 50 companies. Our clients include leaders in the pharmaceuticals, communications, healthcare, information technology, insurance, investment and transportation industries.

For more information, visit www.drinkerbiddle.com/.

PRTM is a leader in global supply chain management, product and service development, and customer value management—the operational areas that allow a company to execute its business strategy flawlessly. In fact, over the last decade, PRTM engagements have represented a total ROI of more than 200:1—resulting in more than $300 billion in value creation for clients.

For more information, visit www.prtm.com/.

Tiber Creek Partners provides subject matter expertise, including scientific and business counseling, to biotechnology companies that seek to use non-dilutive capital from the U.S. Government, foreign governments, and non-governmental organizations as part of their commercialization objectives. Tiber Creek Partner offers a full understanding of funding and procurement opportunities and helps communication the advantages and the state of development of its clients' technology so that it resonates most effectively with funding and purchasing decision-makers. This approach seeks to maximize success and reduce risk, while ensuring access to novel sources of funding.

For more information, visit www.tibercreekpartners.com/.

Silver Sponsors

Advanced BioHealing, Inc. (ABH) is a leader in commercializing the promise of regenerative medicine. The Company develops and commercializes living cell therapies that repair damaged human tissue and enable the body to heal itself. ABH manufactures TransCyte®, an allogeneic temporary skin substitute approved by the FDA to treat mid-dermal to indeterminate depth (partial-thickness) burn wounds. The Company also manufactures and markets Dermagraft®, an FDA-approved bio-engineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process in patients with diabetic foot ulcers. A privately held company with more than 250 employees, ABH maintains its corporate office in Westport, CT, a 70,000 sq. ft. manufacturing facility in La Jolla, CA, and a research facility in Nashville, TN.

For more information, visit abh.com/.

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company’s lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of life-threatening infections including community-aquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia.

For more information, visit www.advancedlifesciences.com/.

Bavarian Nordic is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company’s non-replicating smallpox vaccine, IMVAMUNE®, is derived from the modified vaccinia virus Ankara. Bavarian Nordic's patented technology, MVA-BN®, has been demonstrated in clinical studies to be one of the world's safest multivalent vaccine vectors for the development of vaccines against various infectious diseases such as smallpox, HIV/AIDS, as well as against breast and prostate cancer.

For more information, visit www.bavarian-nordic.com/.

Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies. CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on the company’s extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs. Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.

For more information, visit www.chimerix-inc.com/.

DynPort Vaccine Company LLC, a CSC company, manages product development programs for U.S. government agencies, and provides consulting services to biotechnology and pharmaceutical companies.

For more information, visit www.csc.com/dvc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

For more information, visit www.emergentbiosolutions.com/.

Founded in 2003, Mapp Biopharmaceutical, Inc. is a privately-held company focused on the development of biopharmaceuticals to address unmet needs in global health and biodefense. Mapp's product development plans include plant-based manufacturing for large, cost- sensitive markets. Mapp's global health pipeline includes products for Alzheimer's disease, Clostridium difficile, HIV/HSV, and RSV. Mapp's biodefense pipeline includes monoclonal antibody-based products for Ebola, Lujo, and Marburg viruses, as well as Clostridium perfringens epsilon toxin, ricin, and Staphylococcal enterotoxin B.

For more information, visit www.mappbio.com.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

At United Therapeutics, we derive tremendous inspiration and satisfaction from our work. Quality of life for our patients is our utmost therapeutic goal. Currently, our revenue-generating products are all in the field of cardiovascular medicine. While building business value in the cardiovascular field, we are also laying important foundations for future franchises in the treatment of cancer and infectious diseases.

For more information, visit www.unither.com/.

Bronze Sponsors

Accelovance Inc., headquartered in Rockville, MD, has a proven approach to accelerating clinical development that delivers study Sponsors optimal results through greater control and productivity. Our staff performance, predictable enrollment, and executive focus produce cost- effective solutions to address our clients’ needs as they define them.

For more information, visit www.accelovance.com/.

Molecular Diagnostic Services (MDS) offers services for your vaccine formulations for desired immunogenicity and efficacy evaluations. .

• Immunogenicity testing on formulated vaccine
• Dose stability
• Dose response studies
• Efficacy testing
• Immunotoxicity (if applicable)
• Developmental and reproductive toxicology
• Passive immunization
• Active immunization
• Development of potency testing for vaccine release
• Safety studies (single, repeat and over dose)
• Qualification and validation studies
• Vaccine purity Characterization
• Biodistribution studies (DNA ; virus –vector and cell based vaccines)
• Tumorigenicity
• Oncogenicity
• Recombinant protein vaccines
• Raw material testing
• Whole cell purity analysis
• Bacterial vaccines (whole cell or subunit)
• Characterization and testing challenges
• Protein characterization for subunit vaccines
• Small Scale GMP Production
• Small Scale Fill and Finish
• Cell Bank Release Testing & Sterility
• Adventitious viruses and retroviruses testing

  For more information, visit www.mds-usa.com/.

  ---

  Trellis Bioscience discovers and develops novel human antibody therapeutics as treatment for infectious disease. The company leverages its proprietary platform technology, CellSpot, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company has built a pipeline of monoclonal antibodies focused on infectious disease, with the most advanced being an IND candidate for treatment of Respiratory Syncytial Virus, licensed to Medimmune.

  For more information, visit www.trellisbio.com/.